Header Logo

RACHEL M. LAYMAN

TitleAssociate Professor
InstitutionMD Anderson
DepartmentGeneral Oncology
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Brufsky A, Liu X, Li B, McRoy L, Chen C, Makari D, Layman RM, Rugo HS. Palbociclib plus aromatase inhibitors in patients with metastatic breast cancer and cardiovascular diseases: real-world effectiveness. Oncologist. 2024 Oct 17. PMID: 39418346.
      Citations:    Fields:    
    2. Mukohara T, Park YH, Sommerhalder D, Yonemori K, Hamilton E, Kim SB, Kim JH, Iwata H, Yamashita T, Layman RM, Mita M, Clay T, Chae YS, Oakman C, Yan F, Kim GM, Im SA, Lindeman GJ, Rugo HS, Liyanage M, Saul M, Le Corre C, Skoura A, Liu L, Li M, LoRusso PM. Author Correction: Inhibition of lysine acetyltransferase KAT6 in ER+HER2- metastatic breast cancer: a phase 1 trial. Nat Med. 2024 Aug; 30(8):2371. PMID: 38914862; PMCID: PMC11333270.
      Citations:    Fields:    
    3. Glencer AC, Wanis KN, Brown S, Lucci A, Sun SX, Adesoye T, DeSnyder SM, Layman R, Woodward WA, Hunt KK, Teshome M. Self-Reported Management of Inflammatory Breast Cancer Among the American Society of Breast Surgeons Membership: Consensus and Opportunities. Ann Surg Oncol. 2024 Oct; 31(11):7326-7334. PMID: 39034365.
      Citations:    Fields:    Translation:Humans
    4. Lim B, Seth S, Yam C, Huo L, Fujii T, Lee J, Bassett R, Nasser S, Ravenberg L, White J, Clayborn A, Guerra G, Litton JK, Damodaran S, Layman R, Valero V, Tripathy D, Lewis M, Dobrolecki LE, Lei J, Candelaria R, Arun B, Rauch G, Zhao L, Zhang J, Ding Q, Symmans WF, Chang JT, Thompson AM, Moulder SL, Ueno NT. Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into "ARness". Cell Rep Med. 2024 Jun 18; 5(6):101595. PMID: 38838676; PMCID: PMC11228653.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    5. Iwase T, Cohen EN, Gao H, Alexander A, Kai M, Chiv V, Wang X, Krishnamurthy S, Liu D, Shen Y, Kida K, Reuben A, Layman RM, Ramirez DL, Tripathy D, Moulder SL, Yam C, Valero V, Lim B, Reuben JM, Ueno NT. Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy. Clin Cancer Res. 2024 Jun 03; 30(11):2424-2432. PMID: 38629963; PMCID: PMC11147689.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    6. Mukohara T, Park YH, Sommerhalder D, Yonemori K, Hamilton E, Kim SB, Kim JH, Iwata H, Yamashita T, Layman RM, Mita M, Clay T, Chae YS, Oakman C, Yan F, Kim GM, Im SA, Lindeman GJ, Rugo HS, Liyanage M, Saul M, Le Corre C, Skoura A, Liu L, Li M, LoRusso PM. Inhibition of lysine acetyltransferase KAT6 in ER+HER2- metastatic breast cancer: a phase 1 trial. Nat Med. 2024 Aug; 30(8):2242-2250. PMID: 38824244; PMCID: PMC11333285.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    7. Brufsky A, Liu X, Li B, McRoy L, Chen C, Layman RM, Rugo HS. Treatment outcomes in older patients with metastatic breast cancer receiving palbociclib plus an aromatase inhibitor: a plain language summary. Future Oncol. 2024; 20(19):1309-1317. PMID: 38536033; PMCID: PMC11333972.
      Citations:    Fields:    Translation:Humans
    8. Layman RM, Han HS, Rugo HS, Stringer-Reasor EM, Specht JM, Dees EC, Kabos P, Suzuki S, Mutka SC, Sullivan BF, Gorbatchevsky I, Wesolowski R. Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study. Lancet Oncol. 2024 Apr; 25(4):474-487. PMID: 38547892.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    9. Rugo HS, Liu X, Li B, McRoy L, Chen C, Layman RM, Tomlin-Harris T, Brufsky A. Prolonging the lives of African-Americans with metastatic breast cancer by adding palbociclib to an aromatase inhibitor in routine clinical practice: a plain language summary of a real-world database study. Future Oncol. 2024; 20(19):1299-1307. PMID: 38517416; PMCID: PMC11333971.
      Citations: 1     Fields:    Translation:Humans
    10. Mouabbi JA, Qaio W, Shen Y, Raghavendra AS, Tripathy D, Layman RM. Efficacy of Single-Agent Chemotherapy in Endocrine Therapy-Refractory Metastatic Invasive Lobular Carcinoma. Oncologist. 2024 Mar 04; 29(3):213-218. PMID: 38070191; PMCID: PMC10911914.
      Citations:    Fields:    Translation:Humans
    11. Provencher L, Cescon DW, Hilton J, Morales Murilo S, Layman RM, Pluard T, Yeo B, Park IH, Kim SB, Im YH, Wyce A, Krishnatry AS, Hicks K, Zhang Q, Barbash O, Khaled A, Horner T, Dhar A, Oliveira M, Sparano JA. A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor-positive/HER2-negative Advanced or Metastatic Breast Cancer. Clin Cancer Res. 2024 01 17; 30(2):334-343. PMID: 37992310; PMCID: PMC10792358.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    12. Nakhlis F, Niman SM, Ueno NT, Troll E, Ryan S, Yeh E, Warren L, Bellon J, Harrison B, Iwase T, Carisa Le-Petross HT, Saleem S, Teshome M, Whitman GJ, Woodward WA, Overmoyer B, Tolaney SM, Regan M, Lynce F, Layman RM. Clinical outcomes after 1 versus 2-3 lines of neoadjuvant therapy in stage III inflammatory breast cancer. Breast Cancer Res Treat. 2024 Apr; 204(2):289-297. PMID: 38155272.
      Citations:    Fields:    Translation:Humans
    13. Brufsky A, Liu X, Li B, McRoy L, Chen C, Layman RM, Rugo HS. Palbociclib Combined with an Aromatase Inhibitor in Patients with Breast Cancer with Lung or Liver Metastases in US Clinical Practice. Cancers (Basel). 2023 Nov 02; 15(21). PMID: 37958441; PMCID: PMC10649131.
      Citations:    
    14. Rugo HS, Liu X, Li B, McRoy L, Chen C, Layman RM, Brufsky A. Real-world treatment patterns for palbociclib plus an aromatase inhibitor, or an aromatase inhibitor alone, for patients with metastatic breast cancer in the Flatiron Database. Int J Cancer. 2024 Feb 15; 154(4):701-711. PMID: 37831416.
      Citations:    Fields:    Translation:Humans
    15. Rugo HS, Liu X, Li B, McRoy L, Chen C, Layman RM, Brufsky A. Real-World Effectiveness of Palbociclib Plus Aromatase Inhibitors in African American Patients With Metastatic Breast Cancer. Oncologist. 2023 10 03; 28(10):866-874. PMID: 37487056; PMCID: PMC10546832.
      Citations:    Fields:    Translation:Humans
    16. Brufsky A, Liu X, Li B, McRoy L, Chen C, Layman RM, Rugo HS. Real-world treatment patterns and effectiveness of palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer aged 75 years or older. Front Oncol. 2023; 13:1237751. PMID: 37841423; PMCID: PMC10569486.
      Citations:    
    17. Mouabbi JA, Raghavendra AS, Bassett RL, Christgen M, Middleton L, Teshome M, Nasrazadani A, Hortobagyi G, Hassan A, Tripathy D, Layman RM. Absence of lobular carcinoma in situ is a poor prognostic marker in invasive lobular carcinoma. Eur J Cancer. 2023 09; 191:113250. PMID: 37573674; PMCID: PMC10529602.
      Citations:    Fields:    Translation:Humans
    18. Mouabbi JA, Singareeka Raghavendra A, Bassett RL, Hassan A, Tripathy D, Layman RM. Survival Outcomes in Patients With Hormone Receptor-Positive Metastatic Breast Cancer With Low or No ERBB2 Expression Treated With Targeted Therapies Plus Endocrine Therapy. JAMA Netw Open. 2023 05 01; 6(5):e2313017. PMID: 37166793; PMCID: PMC10176119.
      Citations: 3     Fields:    Translation:Humans
    19. Yam C, Mittendorf EA, Garber HR, Sun R, Damodaran S, Murthy RK, Ramirez D, Karuturi M, Layman RM, Ibrahim N, Rauch GM, Adrada BE, Candelaria RP, White JB, Ravenberg E, Clayborn A, Ding QQ, Symmans WF, Prabhakaran S, Thompson AM, Valero V, Tripathy D, Huo L, Moulder SL, Litton JK. A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer. Breast Cancer Res Treat. 2023 Jun; 199(3):457-469. PMID: 37061619.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    20. Abuhadra N, Sun R, Bassett RL, Huo L, Chang JT, Teshome M, Clayborn AR, White JB, Ravenberg EE, Adrada BE, Candelaria RP, Yang W, Ding Q, Symmans WF, Arun B, Damodaran S, Koenig KB, Layman RM, Lim B, Litton JK, Thompson A, Ueno NT, Piwnica-Worms H, Hortobagyi GN, Valero V, Tripathy D, Rauch GM, Moulder S, Yam C. Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy. Invest New Drugs. 2023 Jun; 41(3):391-401. PMID: 37043123.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    21. Rugo HS, Liu X, Li B, McRoy L, Layman RM, Brufsky A. Real-world comparative effectiveness of palbociclib plus letrozole versus letrozole in older patients with metastatic breast cancer. Breast. 2023 Jun; 69:375-381. PMID: 37080011; PMCID: PMC10127113.
      Citations: 1     Fields:    Translation:Humans
    22. Mouabbi JA, Raghavendra AS, Bassett RL, Hassan A, Tripathy D, Layman RM. Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies. NPJ Breast Cancer. 2022 Dec 20; 8(1):131. PMID: 36539444; PMCID: PMC9768132.
      Citations: 1     
    23. Corrigan KL, Kouzy R, Jaoude JA, Patel RR, Layman RM, Giordano SH, Woodward WA, Smith BD, Shaitelman SF, Ludmir EB. Inclusion of premenopausal women in breast cancer clinical trials. Breast. 2022 Dec; 66:204-207. PMID: 36327626; PMCID: PMC9637813.
      Citations:    Fields:    
    24. Rugo HS, Brufsky A, Liu X, Li B, McRoy L, Chen C, Layman RM, Cristofanilli M, Torres MA, Curigliano G, Finn RS, DeMichele A. Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer. NPJ Breast Cancer. 2022 Oct 11; 8(1):114. PMID: 36220852; PMCID: PMC9553912.
      Citations: 12     
    25. Cobb AN, Diao K, Teshome M, Lucci A, Ueno NT, Stauder M, Layman RM, Kuerer HM, Woodward WA, Sun SX. Long-term Oncologic Outcomes in Patients with Inflammatory Breast Cancer with Supraclavicular Nodal Involvement. Ann Surg Oncol. 2022 Oct; 29(10):6381-6392. PMID: 35834145.
      Citations:    Fields:    
    26. Brufsky A, Liu X, Li B, McRoy L, Layman RM. Real-World Effectiveness of Palbociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer With Lung or Liver Metastases: Flatiron Database Analysis. Front Oncol. 2022; 12:865292. PMID: 35860587; PMCID: PMC9291245.
      Citations:    
    27. Patt D, Liu X, Li B, McRoy L, Layman RM, Brufsky A. Real-World Treatment Patterns and Outcomes of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis. Clin Breast Cancer. 2022 08; 22(6):601-610. PMID: 35643624.
      Citations:    Fields:    
    28. Mouabbi JA, Hassan A, Lim B, Hortobagyi GN, Tripathy D, Layman RM. Invasive lobular carcinoma: an understudied emergent subtype of breast cancer. Breast Cancer Res Treat. 2022 Jun; 193(2):253-264. PMID: 35347549.
      Citations: 1     Fields:    Translation:Humans
    29. Ha MJ, Singareeka Raghavendra A, Kettner NM, Qiao W, Damodaran S, Layman RM, Hunt KK, Shen Y, Tripathy D, Keyomarsi K. Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting: A large institutional study. Int J Cancer. 2022 06 15; 150(12):2025-2037. PMID: 35133007; PMCID: PMC9018572.
      Citations:    Fields:    Translation:Humans
    30. Layman RM, Lin H, Gutierrez Barrera AM, Karuturi MS, Yam C, Arun BK. Clinical outcomes and Oncotype DX Breast Recurrence Score? in early-stage BRCA-associated hormone receptor-positive breast cancer. Cancer Med. 2022 03; 11(6):1474-1483. PMID: 35128817; PMCID: PMC8921901.
      Citations: 1     Fields:    Translation:Humans
    31. Brufsky A, Liu X, Li B, McRoy L, Layman RM. Correction to: Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice. Target Oncol. 2021 Nov; 16(6):865. PMID: 34652714; PMCID: PMC9172681.
      Citations:    Fields:    
    32. Jhaveri K, Juric D, Yap YS, Cresta S, Layman RM, Duhoux FP, Takahashi S, Huober J, Kundamal N, Sheng Q, Balbin A, Ji Y, He W, Crystal A, De Vita S, Curigliano G, Terret C. A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer. Clin Cancer Res. 2021 11 01; 27(21):5760-5770. PMID: 34433648; PMCID: PMC9401512.
      Citations: 2     Fields:    Translation:Humans
    33. Brufsky A, Liu X, Li B, McRoy L, Layman RM. Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice. Target Oncol. 2021 09; 16(5):601-611. PMID: 34338965; PMCID: PMC8484164.
      Citations:    Fields:    Translation:Humans
    34. DeMichele A, Cristofanilli M, Brufsky A, Liu X, Mardekian J, McRoy L, Layman RM, Emir B, Torres MA, Rugo HS, Finn RS. Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice. Breast Cancer Res. 2021 03 24; 23(1):37. PMID: 33761995; PMCID: PMC7989035.
      Citations: 11     Fields:    Translation:Humans
    35. Lin JS, Mamlouk O, Selamet U, Tchakarov A, Glass WF, Sheth RA, Layman RM, Dadu R, Abdelwahab N, Abdelrahim M, Diab A, Yee C, Abudayyeh A. Infliximab for the treatment of patients with checkpoint inhibitor-associated acute tubular interstitial nephritis. Oncoimmunology. 2021 02 02; 10(1):1877415. PMID: 33643693; PMCID: PMC7872057.
      Citations: 4     Fields:    Translation:Humans
    36. Layman RM, Arun B. PARP Inhibitors in Triple-Negative Breast Cancer Including Those With BRCA Mutations. Cancer J. 2021 Jan-Feb 01; 27(1):67-75. PMID: 33475295.
      Citations: 2     Fields:    Translation:HumansCells
    37. Lau R, Du L, Chen E, Fu C, Gould R, Marczyk M, Layman R, Bedrosian I, Valero V, Symmans WF, Sinn BV. Technical Validity of a Customized Assay of Sensitivity to Endocrine Therapy Using Sections from Fixed Breast Cancer Tissue. Clin Chem. 2020 07 01; 66(7):934-945. PMID: 32613237.
      Citations:    Fields:    Translation:Humans
    38. Wesolowski R, Stover DG, Lustberg MB, Shoben A, Zhao M, Mrozek E, Layman RM, Macrae E, Duan W, Zhang J, Hall N, Wright CL, Gillespie S, Berger M, Chalmers JJ, Carey A, Balasubramanian P, Miller BL, Amaya P, Andreopoulou E, Sparano J, Shapiro CL, Villalona-Calero MA, Geyer S, Chen A, Grever MR, Knopp MV, Ramaswamy B. Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker Study. Oncologist. 2020 08; 25(8):e1158-e1169. PMID: 32452601; PMCID: PMC7418347.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    39. Bayraktar S, Zhou JZ, Bassett R, Gutierrez Barrera AM, Layman RM, Valero V, Arun B. Clinical outcome and toxicity from taxanes in breast cancer patients with BRCA1 and BRCA2 pathogenic germline mutations. Breast J. 2020 08; 26(8):1572-1582. PMID: 32497289.
      Citations: 1     Fields:    Translation:Humans
    40. Wesolowski R, Stiff A, Quiroga D, McQuinn C, Li Z, Nitta H, Savardekar H, Benner B, Ramaswamy B, Lustberg M, Layman RM, Macrae E, Kassem M, Williams N, Sardesai S, VanDeusen J, Stover D, Cherian M, Mace TA, Yu L, Duggan M, Carson WE. Exploratory analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients receiving neo-adjuvant chemotherapy for operable breast cancer. BMC Cancer. 2020 May 19; 20(1):445. PMID: 32429929; PMCID: PMC7236344.
      Citations: 7     Fields:    Translation:HumansCells
    41. Iwase T, Harano K, Masuda H, Kida K, Hess KR, Wang Y, Dirix L, Van Laere SJ, Lucci A, Krishnamurthy S, Woodward WA, Layman RM, Ueno NT, Bertucci F. Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC. BMC Cancer. 2020 May 18; 20(1):430. PMID: 32423453; PMCID: PMC7236459.
      Citations: 2     Fields:    Translation:Humans
    42. Sardesai S, Badawi M, Mrozek E, Morgan E, Phelps M, Stephens J, Wei L, Kassem M, Ling Y, Lustberg M, Stover D, Williams N, Layman R, Reinbolt R, VanDeusen J, Cherian M, Grever M, Carson W, Ramaswamy B, Wesolowski R. A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer. Invest New Drugs. 2020 10; 38(5):1400-1410. PMID: 31953695; PMCID: PMC7955776.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    43. Sinn BV, Fu C, Lau R, Litton J, Tsai TH, Murthy R, Tam A, Andreopoulou E, Gong Y, Murthy R, Gould R, Zhang Y, King TA, Viale A, Andrade V, Giri D, Salgado R, Laios I, Sotiriou C, Marginean EC, Kwiatkowski DN, Layman RM, Booser D, Hatzis C, Vicente Valero V, Fraser Symmans W. SETER/PR: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer. NPJ Breast Cancer. 2019; 5:16. PMID: 31231679; PMCID: PMC6542807.
      Citations: 16     
    44. Layman RM. CDK4/6 Inhibitors for Advanced Hormone Receptor-Positive Breast Cancer, 2019 and Beyond. J Natl Compr Canc Netw. 2019 02; 17(2):190-192. PMID: 30787131.
      Citations: 3     Fields:    Translation:Humans
    45. Makary MS, Lionberg A, Khayat M, Lustberg MB, AlTaani J, Pan XJ, Layman RR, Raman SV, Layman RM, Dowell JD. Advanced stage breast cancer is associated with catheter-tip thrombus formation following implantable central venous port placement. Phlebology. 2019 Mar; 34(2):107-114. PMID: 29771187.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    46. Vijayaraghavan S, Moulder S, Keyomarsi K, Layman RM. Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions. Target Oncol. 2018 02; 13(1):21-38. PMID: 29218622.
      Citations: 33     Fields:    Translation:Humans
    47. Lustberg MB, Orchard TS, Reinbolt R, Andridge R, Pan X, Belury M, Cole R, Logan A, Layman R, Ramaswamy B, Wesolowski R, Berger M, Patterson E, Loprinzi C, Shapiro CL, Yee L. Randomized placebo-controlled pilot trial of omega 3 fatty acids for prevention of aromatase inhibitor-induced musculoskeletal pain. Breast Cancer Res Treat. 2018 02; 167(3):709-718. PMID: 29101597; PMCID: PMC5809189.
      Citations: 12     Fields:    Translation:Humans
    48. Abdel-Rasoul M, Carson WE, Wesolowski R, Duggan MC, Stiff A, Markowitz J, Trikha P, Levine KM, Schoenfield L, Layman R, Ramaswamy B, Macrae ER, Lustberg MB, Reinbolt RE, Mrozek E, Byrd JC, Caligiuri MA, Mace TA. Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer. Cancer Immunol Immunother. 2017 Nov; 66(11):1437-1447. PMID: 28688082; PMCID: PMC5647220.
      Citations: 28     Fields:    Translation:HumansCells
    49. Vahdat LT, Layman R, Yardley DA, Gradishar W, Salkeni MA, Joy AA, Garcia AA, Ward P, Khatcheressian J, Sparano J, Rodriguez G, Tang S, Gao L, Dalal RP, Kauh J, Miller K. Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer. Oncologist. 2017 03; 22(3):245-254. PMID: 28220020; PMCID: PMC5344637.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    50. Gradishar WJ, Yardley DA, Layman R, Sparano JA, Chuang E, Northfelt DW, Schwartz GN, Youssoufian H, Tang S, Novosiadly R, Forest A, Nguyen TS, Cosaert J, Grebennik D, Haluska P. Clinical and Translational Results of a Phase II, Randomized Trial of an Anti-IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy. Clin Cancer Res. 2016 Jan 15; 22(2):301-9. PMID: 26324738; PMCID: PMC5548297.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    51. Bevers TB, Ward JH, Arun BK, Colditz GA, Cowan KH, Daly MB, Garber JE, Gemignani ML, Gradishar WJ, Jordan JA, Korde LA, Kounalakis N, Krontiras H, Kumar S, Kurian A, Laronga C, Layman RM, Loftus LS, Mahoney MC, Merajver SD, Meszoely IM, Mortimer J, Newman L, Pritchard E, Pruthi S, Seewaldt V, Specht MC, Visvanathan K, Wallace A, Bergman MA, Kumar R. Breast Cancer Risk Reduction, Version 2.2015. J Natl Compr Canc Netw. 2015 Jul; 13(7):880-915. PMID: 26150582.
      Citations: 16     Fields:    Translation:Humans
    52. Hicks M, Macrae ER, Abdel-Rasoul M, Layman R, Friedman S, Querry J, Lustberg M, Ramaswamy B, Mrozek E, Shapiro C, Wesolowski R. Neoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic complete response in patients with early stage HER2-positive breast cancer: a meta-analysis of randomized prospective clinical trials. Oncologist. 2015 Apr; 20(4):337-43. PMID: 25732265; PMCID: PMC4391765.
      Citations: 17     Fields:    Translation:Humans
    53. Berger MJ, Vargo C, Vincent M, Shaver K, Phillips G, Layman R, Macrae E, Mrozek E, Ramaswamy B, Wesolowski R, Shapiro CL, Lustberg MB. Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction. Support Care Cancer. 2015 Jul; 23(7):2019-24. PMID: 25519756; PMCID: PMC4804339.
      Citations: 8     Fields:    Translation:Humans
    54. Zhao M, Pan X, Layman R, Lustberg MB, Mrozek E, Macrae ER, Wesolowski R, Carothers S, Puhalla S, Shapiro CL, Ramaswamy B. A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer. Invest New Drugs. 2014 Dec; 32(6):1285-94. PMID: 24894652; PMCID: PMC4303337.
      Citations: 9     Fields:    Translation:HumansCellsCTClinical Trials
    55. Lustberg MB, Balasubramanian P, Miller B, Garcia-Villa A, Deighan C, Wu Y, Carothers S, Berger M, Ramaswamy B, Macrae ER, Wesolowski R, Layman RM, Mrozek E, Pan X, Summers TA, Shapiro CL, Chalmers JJ. Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients. Breast Cancer Res. 2014 Mar 06; 16(2):R23. PMID: 24602188; PMCID: PMC4053256.
      Citations: 47     Fields:    Translation:HumansCells
    56. Layman R, Ramaswamy B, Lustberg M, Vecchione A, Knopp MV, Shapiro CL, Mr?zek E. Phase II trial of neoadjuvant weekly nanoparticle albumin-bound paclitaxel, carboplatin, and biweekly bevacizumab therapy in women with clinical stage II or III HER2-negative breast cancer. Clin Breast Cancer. 2014 Aug; 14(4):228-34. PMID: 24703985; PMCID: PMC4104207.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    57. Wenzell CM, Berger MJ, Blazer MA, Crawford BS, Griffith NL, Wesolowski R, Lustberg MB, Phillips GS, Ramaswamy B, Mrozek E, Flynn JM, Shapiro CL, Layman RM. Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy. Support Care Cancer. 2013 Oct; 21(10):2845-51. PMID: 23748485; PMCID: PMC3769492.
      Citations: 9     Fields:    Translation:Humans
    58. Poi MJ, Berger M, Lustberg M, Layman R, Shapiro CL, Ramaswamy B, Mrozek E, Olson E, Wesolowski R. Docetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review. Support Care Cancer. 2013 Oct; 21(10):2679-86. PMID: 23686402; PMCID: PMC3769512.
      Citations:    
    59. Layman RM, Ruppert AS, Lynn M, Mrozek E, Ramaswamy B, Lustberg MB, Wesolowski R, Ottman S, Carothers S, Bingman A, Reinbolt R, Kraut EH, Shapiro CL. Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer. Cancer Chemother Pharmacol. 2013 May; 71(5):1183-90. PMID: 23430121; PMCID: PMC3710373.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    60. Schott AF, Landis MD, Dontu G, Griffith KA, Layman RM, Krop I, Paskett LA, Wong H, Dobrolecki LE, Lewis MT, Froehlich AM, Paranilam J, Hayes DF, Wicha MS, Chang JC. Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors. Clin Cancer Res. 2013 Mar 15; 19(6):1512-24. PMID: 23340294; PMCID: PMC3602220.
      Citations: 107     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    61. Layman R, Ramaswamy B, Schaaf L, Li X, Ottman S, Shapiro CL, Mr?zek E. Phase II trial of exemestane in combination with fulvestrant in postmenopausal women with advanced, hormone-responsive breast cancer. Clin Breast Cancer. 2012 Apr; 12(2):151-6. PMID: 22444722; PMCID: PMC5003403.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    62. Reinbolt RE, Alam S, Layman R, Shapiro C, Lustberg M. Pneumocystis jiroveci Pneumonia in an Atypical Host. Clin Breast Cancer. 2012 Apr; 12(2):138-41. PMID: 22133356; PMCID: PMC3498486.
      Citations: 4     Fields:    Translation:HumansAnimals
    63. Lustberg MB, Povoski SP, Zhao W, Ziegler RM, Sugimoto Y, Ruppert AS, Lehman AM, Shiels DR, Mrozek E, Ramaswamy B, Layman RM, Brueggemeier RW, Shapiro CL. Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer. Clin Breast Cancer. 2011 Aug; 11(4):221-7. PMID: 21729671; PMCID: PMC3440773.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    64. Layman RM, Thomas DG, Griffith KA, Smerage JB, Helvie MA, Roubidoux MA, Diehl KM, Newman LA, Sabel MS, Hayman JA, Pierce LJ, Hayes DF, Schott AF. Neoadjuvant docetaxel and capecitabine and the use of thymidine phosphorylase as a predictive biomarker in breast cancer. Clin Cancer Res. 2007 Jul 15; 13(14):4092-7. PMID: 17634534.
      Citations: 6     Fields:    Translation:Humans
    65. Lee KC, Moffat BA, Schott AF, Layman R, Ellingworth S, Juliar R, Khan AP, Helvie M, Meyer CR, Chenevert TL, Rehemtulla A, Ross BD. Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 1):443-50. PMID: 17255264.
      Citations:    
    66. Neoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic completeresponse in patients with early stage HER2-positive breast cancer. Oncologist. 20:337-343.
    67. Yoga and self-reported cognitive problems in breast cancer survivors. Psycho-Oncology. 24:958-966.
    68. Clinical and Translational Results of a Phase II, Randomized Trial of an AntiIGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy. Clinical Cancer Research. 22:301-309.
    LAYMAN's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (240)
    Explore
    _
    Co-Authors (50)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _